Document 0804
 DOCN  M9480804
 TI    Combination therapy for infection due to human immunodeficiency virus
       type 1.
 DT    9410
 AU    Caliendo AM; Hirsch MS; Infectious Disease Unit, Massachusetts General
       Hospital, Boston; 02114.
 SO    Clin Infect Dis. 1994 Apr;18(4):516-24. Unique Identifier : AIDSLINE
       MED/94312547
 AB    The preliminary results of the Concorde trial demonstrated the transient
       clinical benefit of monotherapy with zidovudine (AZT) in asymptomatic
       persons infected with human immunodeficiency virus type 1 (HIV-1). This
       result, which has been widely disseminated and discussed, was
       predictable given the previous demonstration of the development of
       resistance to AZT in isolates from individuals receiving prolonged
       treatment with the drug and given the finding that didanosine (ddI) is
       more efficacious than continued therapy with AZT in individuals who have
       received > or = 6 months of AZT monotherapy. On the basis of these
       findings, interest in combinations of antiretroviral agents has
       continued to grow. Many in vitro studies of nucleoside and nonnucleoside
       inhibitors of reverse transcriptase combined with interferon-alpha or
       inhibitors of protease have been published. In addition, numerous
       clinical trials of various combinations have been completed or are under
       way. Dr. Martin Hirsch and his colleagues at the Massachusetts General
       Hospital have been among the leaders of this effort. He and Dr. Angela
       Caliendo review, in this AIDS Commentary, the current state of our
       knowledge regarding the potential utility of combination therapy for
       infection with HIV-1.
 DE    Acyclovir/ADMINISTRATION & DOSAGE  Antigens, CD4/ADMINISTRATION & DOSAGE
       Antiviral Agents/*ADMINISTRATION & DOSAGE  Clinical Trials  Combined
       Modality Therapy  Didanosine/ADMINISTRATION & DOSAGE  Drug Therapy,
       Combination  Foscarnet/ADMINISTRATION & DOSAGE  Human  HIV
       Infections/*DRUG THERAPY/THERAPY  *HIV-1  In Vitro  Interferon
       Alfa-2a/ADMINISTRATION & DOSAGE  Reverse Transcriptase/ANTAGONISTS &
       INHIB  Zalcitabine/ADMINISTRATION & DOSAGE  Zidovudine/ADMINISTRATION &
       DOSAGE  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).